go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

New Jersey rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $630,957 · 10th–90th $8,710$1,348,9630%10%10th90th$630,957Professionalmedian $489,779 · 10th–90th $467,735$588,8440%50%10th90th$489,779$200.0$1.0K$5.0K$20.0K$100.0K$500.0K$2.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$645,654.23
Typical High
$1,621,810.10
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
Cigna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
Emblem Health
Setting
Professional
Modifier
Global
Typical Low
$416,869.38
Median
$467,735.14
Typical High
$794,328.23
Horizon BCBS
Setting
Facility
Modifier
Global
Typical Low
$1,737.80
Median
$15,488.17
Typical High
$1,230,268.77
Horizon BCBS
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$489,778.82
United
Setting
Facility
Modifier
Global
Typical Low
$398,107.17
Median
$602,559.59
Typical High
$933,254.30
United
Setting
Professional
Modifier
Global
Typical Low
$363,078.05
Median
$467,735.14
Typical High
$660,693.45